Moderna’s preliminary data suggests that its updated COVID-19 vaccine can effectively combat expected variants this fall, including Eris and Fornax. This news comes amid a recent surge in COVID cases across the US. Moderna and Pfizer/BioNTech hope for FDA approval for their updated vaccines in time for the fall. Additionally, Novavax is seeking FDA emergency use authorization for its protein-based vaccine against the XBB strain. Despite this, uncertainty about future vaccine demand is causing drugmakers to consider cost cuts. Pfizer and BioNTech plan to cut R&D spending, while Moderna focuses on mRNA projects such as their RSV and cancer vaccines.
To read more, click here.
[Source: Endpoints News, August 18th, 2023]